Viral Vector News and Research

RSS

Viral Vector is a type of virus used in cancer therapy. The virus is changed in the laboratory and cannot cause disease. Viral vectors may produce tumor antigens (proteins found on a tumor cell) to stimulate an antitumor immune response in the body. Viral vectors may also be used to carry genes that can change cancer cells back to normal cells.

Curia to Acquire US-based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics

Curia today announced it has entered into a definitive agreement to acquire LakePharma Inc.

From Curia 14 Jul 2021

Gene therapy shows promise in children with devastating genetic disorder

Children with a devastating genetic disorder characterized by severe motor disability and developmental delay have experienced sometimes dramatic improvements in a gene therapy trial launched at UCSF Benioff Children's Hospitals.

12 Jul 2021

Novel method of gene therapy promises to transform the treatment of rare genetic disorder

A novel method of gene therapy is helping children born with a rare genetic disorder called AADC deficiency that causes severe physical and developmental disabilities.

12 Jul 2021

COVID-19 recovered vaccinated individuals more protected from Delta variant

The B.1.617 lineage of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first detected in October 2020, has led to new outbreaks of the infection and new waves of the pandemic. This infectious lineage has resulted in the generation of sub-lineages such as B.1.617.1 (Kappa), B.1.617.2 (Delta) and B.1.617.3.

6 Jul 2021

PerkinElmer to buy SIRION Biotech

PerkinElmer Inc. agreed to buy SIRION Biotech GmbH, a provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies. The acquisition is expected to close during the third quarter of 2021.

From Revvity 24 Jun 2021

Targeting lung inflammation with cell membrane-based dexamethasone nanodelivery platform

Recently, researchers discuss their development of cell membrane-based nanoparticles that successfully delivered dexamethasone directly to inflamed lung cells.

21 Jun 2021

Immune cell-mimicking nanoparticles deliver drugs directly to inflamed lungs

Nanoengineers at the University of California San Diego have developed immune cell-mimicking nanoparticles that target inflammation in the lungs and deliver drugs directly where they're needed. As a proof of concept, the researchers filled the nanoparticles with the drug dexamethasone and administered them to mice with inflamed lung tissue.

17 Jun 2021

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

A new study, released as a preprint on the bioRxiv* server, describes the late-stage clinical trial efficacy of a new vaccine candidate based on a deoxyribonucleic acid (DNA) plasmid platform expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Among different constructs of the vaccine plasmid, the RBD was found to produce the most potent and broad immune response.

16 Jun 2021

SARS-CoV-2 oral vaccine booster shows promise in animal tests

In a recent study published on the pre-print bioRxiv* server, a group of Israeli researchers discusses their progress towards developing an oral multi-antigen SARS-CoV-2 vaccine.

15 Jun 2021

Study reports on the immunogenicity of single-shot COVID-19 vaccine against SARS-CoV-2 variants

In the three months since Johnson & Johnson's COVID-19 vaccine received emergency use authorization from the U.S. Food and Drug Administration, more than 10 million Americans have received the vaccine, according to the Centers for Disease Control and Prevention.

9 Jun 2021

Researchers review environmental risk assessments for recombinant COVID-19 viral vector vaccines

In a recent review, published in the journal Vaccines, researchers in Belgium look at the recombinant viral vector-vaccine candidates that are primarily against SARS-CoV-2 still in development and discuss their features from an environmental risk point of view.

8 Jun 2021

Researchers develop proof-of-concept treatment for blood disorders

Researchers at Children's Hospital of Philadelphia (CHOP) have developed a proof-of-concept treatment for blood disorders like sickle cell disease and beta-thalassemia that could raise hemoglobin levels by activating production of both fetal and adult hemoglobin.

1 Jun 2021

Study shows CoronaVac to have high seroconversion rate after 40 days

Researchers from the Federal University of Paraná, Brazil, looked into the seroconversion rate after vaccination with the CoronaVac. Using immunoassays, they measured the immunoglobulins (IgG) for anti-nucleocapsid protein (anti-N) antibodies and anti-spike-1 (anti-S1) protein antibodies.

27 May 2021

Researchers identify aluminum hydroxide/TLR9 agonist as potential adjuvant to improve RBD-based COVID-19 vaccine efficacy

The study findings reveal that RBD-based vaccines adjuvanted with the formulation can induce strong anti-SARS-CoV-2 neutralizing immunity in young and aged mice. The study is currently available on the bioRxiv* preprint server.

24 May 2021

Sequentia collaborated with Nextbiomics to obtain a novel immunization model against COVID-19

Sequentia Biotech and NextBiomics announced the filing of a patent application for a bacterial vaccine against the COVID-19 syndrome.

From Sequentia Biotech 19 May 2021

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

A team of scientists from the Washington University School of Medicine and the University of Texas Medical Branch, USA, has recently evaluated the durability and robustness of an adenovirus-vectored, spike-based intranasal COVID-19 vaccine in mice.

11 May 2021

Experimental gene therapy successfully treats children born without an immune system

An experimental form of gene therapy developed by a team of researchers from UCLA and Great Ormond Street Hospital in London has successfully treated 48 of 50 children born with a rare and deadly inherited disorder that leaves them without an immune system.

11 May 2021

The "key" to vaccine development depends on virus’ binding to human cells

New variants of the SARS-CoV-2 virus most likely will necessitate the development of more vaccine options in the years ahead, and a biomedical scientist at Iowa State University believes the "key" to that development lies in the way the virus binds to human cells.

11 May 2021

Researchers use gene therapy to prevent learning, memory loss in Alzheimer's mouse model

Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, have used gene therapy to prevent learning and memory loss in a mouse model of Alzheimer's disease (AD), a key step toward eventually testing the approach in humans with the neurodegenerative disease.

5 May 2021

Albumedix extends research collaboration with Cobra Biologics to optimize viral vector manufacturing

Albumedix Ltd. ('Albumedix'), an emerging leader in the enablement of advanced therapies and recognized global leader in recombinant human albumin (rHA) has today announced an extension to its research collaboration with Cobra Biologics, the gene therapy division of Cognate BioServices, a Charles River Laboratories International, Inc. company.

From Albumedix Ltd. 28 Apr 2021

Viral Vector News and Research

Further Reading

Curia to Acquire US-based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics

Gene therapy shows promise in children with devastating genetic disorder

Novel method of gene therapy promises to transform the treatment of rare genetic disorder

COVID-19 recovered vaccinated individuals more protected from Delta variant

PerkinElmer to buy SIRION Biotech

Targeting lung inflammation with cell membrane-based dexamethasone nanodelivery platform

Immune cell-mimicking nanoparticles deliver drugs directly to inflamed lungs

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

SARS-CoV-2 oral vaccine booster shows promise in animal tests

Study reports on the immunogenicity of single-shot COVID-19 vaccine against SARS-CoV-2 variants

Researchers review environmental risk assessments for recombinant COVID-19 viral vector vaccines

Researchers develop proof-of-concept treatment for blood disorders

Study shows CoronaVac to have high seroconversion rate after 40 days

Researchers identify aluminum hydroxide/TLR9 agonist as potential adjuvant to improve RBD-based COVID-19 vaccine efficacy

Sequentia collaborated with Nextbiomics to obtain a novel immunization model against COVID-19

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

Experimental gene therapy successfully treats children born without an immune system

The "key" to vaccine development depends on virus’ binding to human cells

Researchers use gene therapy to prevent learning, memory loss in Alzheimer's mouse model

Albumedix extends research collaboration with Cobra Biologics to optimize viral vector manufacturing

A guide to advancing biotherapeutic research eBook

Decoding Cannabis: Differentiating Hemp and Marijuana

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Latest Life Science News